Joseph Pantginis Analyst Performance

Managing Director of Equity Research at HC Wainwright

Joseph Pantginis is a stock analyst at HC Wainwright, covering 110 publicly traded companies across a range of sectors. Over the past year, Joseph Pantginis has issued 152 stock ratings, including buy and hold recommendations. While full access to Joseph Pantginis' proprietary MarketBeat Analyst Rating is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Joseph Pantginis' coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rating: Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return: 00.00% 12-Month ROI
Success Rate: 00.00% Profitable Ratings
Total Ratings: 999 Last 11 Years
Buy Recommendations: 96.06% 950 Buy Ratings
Companies Covered: 110 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.4%	4 ratings
Buy	95.7%	946 ratings
Hold	3.8%	38 ratings
Sell	0.1%	1 ratings

Out of 989 total stock ratings issued by Joseph Pantginis at HC Wainwright, the majority (95.7%) have been Buy recommendations, followed by 3.8% Hold, 0.4% Strong Buy, and 0.1% Sell.

Best & Worst Calls

Best Call
000000.0%
CAPR
May 2019
Subscribe to MarketBeat All Access to get analyst recommendation ROI.
Worst Call
000.0%
HGEN
Sep 2021
Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	82.7% of companies on NASDAQ	91 companies
OTCMKTS	5.5% of companies on OTCMKTS	6 companies
NYSEAMERICAN	4.5% of companies on NYSEAMERICAN	5 companies
NYSE	2.7% of companies on NYSE	3 companies
TSE	2.7% of companies on TSE	3 companies
NYSEMKT	0.9% of companies on NYSEMKT	1 company
PINK	0.9% of companies on PINK	1 company

Joseph Pantginis, an analyst at HC Wainwright, currently covers 110 companies listed on NASDAQ, OTCMKTS, NYSEAMERICAN, NYSE, TSE, NYSEMKT and PINK, with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 107 companies	97.3%
	Miscellaneous 3 companies	2.7%

Joseph Pantginis of HC Wainwright specializes in stock coverage within the Medical sector, with additional focus on companies.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 45 companies	40.9%
PHARMACEUTICAL PREPARATIONS 32 companies	29.1%
MED - DRUGS 13 companies	11.8%
BIOTECHNOLOGY 7 companies	6.4%
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC 6 companies	5.5%
Miscellaneous 3 companies	2.7%
MED PRODUCTS 2 companies	1.8%
MEDICAL INFO SYS 1 company	0.9%
SURGICAL & MEDICAL INSTRUMENTS 1 company	0.9%

About Joseph Pantginis

Dr. Pantginis is a Managing Director of Equity Research at H.C. Wainwright whose research focuses on the healthcare sector. Dr. Pantginis conducted more than seventeen years of healthcare equity research. Prior to joining H.C. Wainwright, Dr. Pantginis worked as a Senior Research Analyst and Head of Biotechnology Research at ROTH Capital Partners. Dr. Pantginis also held senior positions at Merriman, Canaccord Adams, Commerce Capital Markets, JBHanauer and Ladenburg. Prior to his equity research career, Dr. Pantginis worked at Regeneron Pharmaceuticals, where he founded the Retroviral Core Facility. Dr. Pantginis’ educational background includes both a Ph.D. and an M.S. in molecular genetics from the Albert Einstein College of Medicine as well as an MBA from Pace University.

Follow on LinkedIn

Time Frame

Start Date

End Date

Rating

12-Month ROIAll ROI

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating
TVTX Travere Therapeutics	9/3/2025	Reiterated Rating	$19.40	$47.00	Buy
TNYA Tenaya Therapeutics	9/2/2025	Reiterated Rating	$1.13	$5.00	Buy
LXRX Lexicon Pharmaceuticals	9/2/2025	Reiterated Rating	$1.11	$4.00	Buy
TVTX Travere Therapeutics	8/28/2025	Boost Price Target	$17.44	$47.00	Buy
LGND Ligand Pharmaceuticals	8/28/2025	Boost Price Target	$160.51	$206.00	Buy
TNYA Tenaya Therapeutics	8/27/2025	Reiterated Rating	$1.08	$5.00	Buy
NEUP Neuphoria Therapeutics	8/26/2025	Reiterated Rating	$7.40	$21.00	Buy
KRYS Krystal Biotech	8/22/2025	Reiterated Rating	$145.70	$240.00	Buy
LSTA Lisata Therapeutics	8/21/2025	Reiterated Rating	$2.40	$15.00	Buy
FBIO Fortress Biotech	8/21/2025	Lower Price Target	$2.05	$17.00	Buy
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter.
CLDX Celldex Therapeutics	8/20/2025	Lower Price Target	$24.02	$42.00	Buy
PHGE BiomX	8/20/2025	Reiterated Rating	$0.55	$15.00	Buy
IOVA Iovance Biotherapeutics	8/19/2025	Reiterated Rating	$2.50	$20.00	Buy
VKTX Viking Therapeutics	8/19/2025	Reiterated Rating	$23.90	$102.00	Buy
ATXS Astria Therapeutics	8/13/2025	Reiterated Rating	$6.65	$16.00	Buy
SNSE Sensei Biotherapeutics	8/5/2025	Reiterated Rating	$8.20	$30.00	Buy
NVCT Nuvectis Pharma	8/4/2025	Lower Price Target	$7.01	$10.00	Buy
VYNE VYNE Therapeutics	7/30/2025	Downgrade	$0.39		Neutral
KRYS Krystal Biotech	7/25/2025	Reiterated Rating	$150.00	$240.00	Buy
CAPR Capricor Therapeutics	7/11/2025	Lower Price Target	$7.94	$24.00	Buy
PDSB PDS Biotechnology	7/1/2025	Reiterated Rating	$1.33	$13.00	Buy
EWTX Edgewise Therapeutics	6/30/2025	Initiated Coverage	$13.17	$42.00	Buy
VKTX Viking Therapeutics	6/25/2025	Reiterated Rating	$26.08	$102.00	Buy
LXRX Lexicon Pharmaceuticals	6/24/2025	Reiterated Rating	$0.73	$4.00	Buy
ATNM Actinium Pharmaceuticals	6/24/2025	Reiterated Rating	$1.52	$4.00	Buy
CAPR Capricor Therapeutics	6/24/2025	Reiterated Rating	$8.47	$77.00	Buy
KRYS Krystal Biotech	6/24/2025	Reiterated Rating	$143.72	$240.00	Buy
LCTX Lineage Cell Therapeutics	6/23/2025	Reiterated Rating	$0.95	$9.00	Buy
CDTX Cidara Therapeutics	6/18/2025	Upgrade	$22.10	$41.00	Buy
ESPR Esperion Therapeutics	6/17/2025	Reiterated Rating	$1.17	$16.00	Buy
BLRX BioLineRx	6/17/2025	Reiterated Rating	$4.67		Buy
CLDX Celldex Therapeutics	6/13/2025	Reiterated Rating	$20.35	$50.00	Buy
CAPR Capricor Therapeutics	6/13/2025	Reiterated Rating	$12.51	$77.00	Buy
ATXS Astria Therapeutics	6/13/2025	Reiterated Rating	$5.89	$16.00	Buy
PDSB PDS Biotechnology	6/11/2025	Reiterated Rating	$1.68	$13.00	Buy
MBRX Moleculin Biotech	6/9/2025	Upgrade	$0.67	$4.00	Buy
PHIO Phio Pharmaceuticals	6/5/2025	Initiated Coverage	$2.10	$14.00	Buy
ATYR aTyr Pharma	6/4/2025	Reiterated Rating	$5.32	$35.00	Buy
ANL Adlai Nortye	6/2/2025	Downgrade	$1.57		Neutral
BLRX BioLineRx	5/28/2025	Reiterated Rating	$3.68		Buy

XOMA XOMA Royalty	5/28/2025	Reiterated Rating	$24.92	$104.00	Buy
CRIS Curis	5/19/2025	Reiterated Rating	$2.03	$17.00	Buy
ATYR aTyr Pharma	5/19/2025	Reiterated Rating	$3.27	$35.00	Buy
ARMP Armata Pharmaceuticals	5/19/2025	Boost Price Target	$1.74	$9.00	Buy
PHGE BiomX	5/16/2025	Lower Price Target	$0.56	$15.00	Buy
CVKD Cadrenal Therapeutics	5/16/2025	Reiterated Rating	$15.14	$32.00	Buy
CALC CalciMedica	5/15/2025	Reiterated Rating	$1.91	$16.00	Buy
ATNM Actinium Pharmaceuticals	5/12/2025	Reiterated Rating	$1.55	$4.00	Buy
IOVA Iovance Biotherapeutics	5/9/2025	Lower Price Target	$3.17	$20.00	Buy
ITRM Iterum Therapeutics	5/8/2025	Reiterated Rating	$0.92	$9.00	Buy
KRYS Krystal Biotech	5/6/2025	Reiterated Rating	$141.18	$240.00	Buy
BMEA Biomea Fusion	5/6/2025	Lower Price Target	$2.00	$18.00	Buy
CLDX Celldex Therapeutics	5/6/2025	Reiterated Rating	$20.29	$80.00	Buy
NVCT Nuvectis Pharma	4/30/2025	Reiterated Rating	$10.33	$15.00	Buy
KRYS Krystal Biotech	4/28/2025	Boost Price Target	$167.35	$240.00	Buy
KURA Kura Oncology	4/28/2025	Reiterated Rating	$6.41	$40.00	Buy
ATNM Actinium Pharmaceuticals	4/28/2025	Reiterated Rating	$1.34	$4.00	Buy
TNYA Tenaya Therapeutics	4/25/2025	Reiterated Rating	$0.46	$5.00	Buy
ESPR Esperion Therapeutics	4/25/2025	Reiterated Rating	$0.88	$16.00	Buy
VYNE VYNE Therapeutics	4/25/2025	Lower Price Target	$1.39	$4.50	Buy
VKTX Viking Therapeutics	4/24/2025	Reiterated Rating	$25.84	$102.00	Buy
CMPX Compass Therapeutics	4/21/2025	Reiterated Rating	$1.78	$24.00	Buy
CYTK Cytokinetics	4/21/2025	Reiterated Rating	$38.01	$120.00	Buy
VKTX Viking Therapeutics	4/17/2025	Reiterated Rating	$23.45	$102.00	Buy
CYTK Cytokinetics	4/15/2025	Reiterated Rating	$39.07	$120.00	Buy
TPST Tempest Therapeutics	4/10/2025	Reiterated Rating	$7.15	$16.00	Neutral
XBIO Xenetic Biosciences	4/9/2025	Reiterated Rating	$2.38		Neutral
CLNN Clene	4/8/2025	Reiterated Rating	$2.99	$31.00	Buy
PHGE BiomX	4/4/2025	Reiterated Rating	$0.59	$21.00	Buy
CMPX Compass Therapeutics	4/4/2025	Boost Price Target	$1.61	$24.00	Buy
CYTK Cytokinetics	4/4/2025	Reiterated Rating	$40.52	$120.00	Buy
KAPA Kairos Pharma	4/3/2025	Initiated Coverage	$0.92	$12.00	Buy
ATNM Actinium Pharmaceuticals	4/1/2025	Reiterated Rating	$1.61	$4.00	Buy
PHGE BiomX	4/1/2025	Boost Price Target	$0.56	$21.00	Buy
CALC CalciMedica	4/1/2025	Reiterated Rating	$1.91	$16.00	Buy
BMEA Biomea Fusion	3/31/2025	Reiterated Rating	$2.30	$40.00	Buy
TNYA Tenaya Therapeutics	3/31/2025	Reiterated Rating	$0.61	$5.00	Buy
BLRX BioLineRx	3/31/2025	Boost Price Target	$3.03	$26.00	Buy
XOMA XOMA Royalty	3/28/2025	Reiterated Rating	$20.97	$104.00	Buy
TPST Tempest Therapeutics	3/28/2025	Lower Price Target	$10.92	$208.00	Buy
LXRX Lexicon Pharmaceuticals	3/28/2025	Reiterated Rating	$0.63	$4.00	Buy
APTO Aptose Biosciences	3/28/2025	Boost Price Target	$3.33	$6.00	Buy
PDSB PDS Biotechnology	3/27/2025	Lower Price Target	$1.25	$13.00	Buy
VKTX Viking Therapeutics	3/26/2025	Reiterated Rating	$26.07	$102.00	Buy
ATNM Actinium Pharmaceuticals	3/25/2025	Reiterated Rating	$1.73	$4.00	Buy
BMEA Biomea Fusion	3/24/2025	Reiterated Rating	$2.87	$40.00	Buy
CLNN Clene	3/24/2025	Reiterated Rating	$4.06	$31.00	Buy
XBIO Xenetic Biosciences	3/20/2025	Reiterated Rating	$3.64		Neutral
PHAR Pharming Group	3/20/2025	Reiterated Rating	$8.86	$37.00	Buy
ESPR Esperion Therapeutics	3/20/2025	Reiterated Rating	$1.62	$16.00	Buy

OABI OmniAb	3/19/2025	Reiterated Rating	$3.19	$11.00	Buy
XOMA XOMA Royalty	3/19/2025	Reiterated Rating	$20.89	$104.00	Buy
ATNM Actinium Pharmaceuticals	3/18/2025	Reiterated Rating	$1.24	$4.00	Buy
CAPR Capricor Therapeutics	3/17/2025	Reiterated Rating	$13.23	$77.00	Buy
ATYR aTyr Pharma	3/14/2025	Reiterated Rating	$3.99	$35.00	Buy
PHAR Pharming Group	3/14/2025	Reiterated Rating	$8.74	$37.00	Buy
PDSB PDS Biotechnology	3/13/2025	Reiterated Rating	$1.27	$21.00	Buy
CLNN Clene	3/12/2025	Reiterated Rating	$4.41	$31.00	Buy
CKPT Checkpoint Therapeutics	3/11/2025	Reiterated Rating	$3.98	$4.10	Neutral
LCTX Lineage Cell Therapeutics	3/11/2025	Reiterated Rating	$0.53	$9.00	Buy
TNYA Tenaya Therapeutics	3/11/2025	Lower Price Target	$0.51	$5.00	Buy
ATNM Actinium Pharmaceuticals	3/11/2025	Reiterated Rating	$1.12	$4.00	Buy
VKTX Viking Therapeutics	3/11/2025	Reiterated Rating	$25.36	$102.00	Buy
ATXS Astria Therapeutics	3/11/2025	Reiterated Rating	$5.91	$16.00	Buy
PDSB PDS Biotechnology	3/7/2025	Reiterated Rating	$1.28	$21.00	Buy
VYNE VYNE Therapeutics	3/6/2025	Reiterated Rating	$2.31	$5.75	Buy
RIGL Rigel Pharmaceuticals	3/5/2025	Reiterated Rating	$22.08	$57.00	Buy
CALC CalciMedica	3/4/2025	Reiterated Rating	$2.20	$16.00	Buy
ESPR Esperion Therapeutics	3/4/2025	Reiterated Rating	$1.76	$16.00	Buy
CAPR Capricor Therapeutics	3/4/2025	Reiterated Rating	$14.23	$77.00	Buy
LXRX Lexicon Pharmaceuticals	3/3/2025	Reiterated Rating	$0.35	$4.00	Buy
IOVA Iovance Biotherapeutics	2/28/2025	Reiterated Rating	$5.26	$32.00	Buy
CLDX Celldex Therapeutics	2/28/2025	Reiterated Rating	$20.31	$80.00	Buy
CYTK Cytokinetics	2/28/2025	Reiterated Rating	$47.45	$120.00	Buy
KRYS Krystal Biotech	2/28/2025	Reiterated Rating	$176.56	$221.00	Buy
KURA Kura Oncology	2/27/2025	Reiterated Rating	$7.77	$40.00	Buy
ATXS Astria Therapeutics	2/27/2025	Reiterated Rating	$6.45	$16.00	Buy
CLNN Clene	2/25/2025	Reiterated Rating	$4.33	$31.00	Buy
NVCT Nuvectis Pharma	2/25/2025	Lower Price Target	$7.06	$11.00	Buy
PDSB PDS Biotechnology	2/24/2025	Reiterated Rating	$1.23	$21.00	Buy
VYNE VYNE Therapeutics	2/19/2025	Reiterated Rating	$2.64	$5.75	Buy
KRYS Krystal Biotech	2/19/2025	Reiterated Rating	$171.70	$221.00	Buy
PTNT Palatin Technologies	2/13/2025	Lower Price Target	$54.25	$350.00	Buy
APTO Aptose Biosciences	2/12/2025	Reiterated Rating	$6.70	$60.00	Buy
ESPR Esperion Therapeutics	2/11/2025	Reiterated Rating	$1.86	$16.00	Buy
LCTX Lineage Cell Therapeutics	2/11/2025	Reiterated Rating	$0.64	$9.00	Buy
PTNT Palatin Technologies	2/7/2025	Reiterated Rating	$49.50	$850.00	Buy
VKTX Viking Therapeutics	2/6/2025	Reiterated Rating	$33.50	$102.00	Buy
KURA Kura Oncology	2/6/2025	Boost Price Target	$9.05	$40.00	Buy
NEUP Neuphoria Therapeutics	2/4/2025	Boost Price Target	$5.10	$21.00	Buy
XOMA XOMA Royalty	2/3/2025	Lower Price Target	$26.61	$104.00	Buy
LCTX Lineage Cell Therapeutics	1/31/2025	Reiterated Rating	$0.63	$9.00	Buy
LXRX Lexicon Pharmaceuticals	1/29/2025	Reiterated Rating	$0.93	$4.00	Buy
PTNT Palatin Technologies	1/28/2025	Reiterated Rating	$46.50	$850.00	Buy
ESPR Esperion Therapeutics	1/23/2025	Reiterated Rating	$2.20	$16.00	Buy
ATXS Astria Therapeutics	1/23/2025	Reiterated Rating	$7.53	$16.00	Buy
RIGL Rigel Pharmaceuticals	1/22/2025	Reiterated Rating	$21.29	$57.00	Buy
CYTK Cytokinetics	1/21/2025	Reiterated Rating	$45.72	$120.00	Buy
VKTX Viking Therapeutics	1/17/2025	Reiterated Rating	$33.66	$102.00	Buy
APRE Aprea Therapeutics	1/15/2025	Reiterated Rating	$3.77	$20.00	Buy

BMEA Biomea Fusion	1/14/2025	Reiterated Rating	$4.15	$40.00	Buy
TNYA Tenaya Therapeutics	1/14/2025	Reiterated Rating	$1.50	$18.00	Buy
RIGL Rigel Pharmaceuticals	1/14/2025	Reiterated Rating	$17.11	$57.00	Buy
VYNE VYNE Therapeutics	1/14/2025	Reiterated Rating	$3.02	$5.75	Buy
ATXS Astria Therapeutics	1/13/2025	Reiterated Rating	$7.27	$16.00	Buy
ESPR Esperion Therapeutics	1/10/2025	Reiterated Rating	$2.17		Buy
CYTK Cytokinetics	1/10/2025	Reiterated Rating	$47.37	$120.00	Buy
APTO Aptose Biosciences	1/10/2025	Reiterated Rating	$6.40	$60.00	Buy
VKTX Viking Therapeutics	1/8/2025	Reiterated Rating	$41.52	$102.00	Buy
CMPX Compass Therapeutics	1/8/2025	Reiterated Rating	$1.77	$10.00	Buy
PHGE BiomX	1/8/2025	Reiterated Rating	$0.74	$2.00	Buy
CYTK Cytokinetics	10/17/2024	Reiterated Rating	$55.28	$120.00	Buy

Stock Forecasts and Research Tools

Today's Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.